← All trials
NCT06647940
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2024
- Primary completion
- Nov 1, 2026
- Completion date
- Mar 1, 2027
- First posted
- Oct 18, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 39
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Shantou UniversityCollaborator
- Shenzhen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Guangzhou Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- The First People's Hospital of Zhaoqing CityCollaborator
- Gansu Provincial HospitalCollaborator
- Sun Yat-Sen UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.